Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2173312 | 0.92 | MAPT (0.61) | MAPTPOLBNR1H4TP53THRB | |
| SCHEMBL2547296 | 0.89 | MAPT (0.69) | MAPTPOLBNR1H4TP53THRB | |
| SCHEMBL2174844 | 0.85 | RAB9A (0.47) | MAPTPOLBNR1H4TP53THRB | |
| SCHEMBL2172534 | 0.80 | MAPT (0.68) | MAPTPOLBNR1H4TP53THRB | |
| SCHEMBL2547306 | 0.79 | MAPT (0.79) | MAPTPOLBNR1H4TP53THRB | |
| SCHEMBL2173369 | 0.79 | NR1H4 (0.53) | MAPTPOLBNR1H4THRB | |
| SCHEMBL22299813 | 0.78 | MAPT (0.54) | MAPTPOLBNR1H4TP53KDM4E | |
| SCHEMBL2171108 | 0.77 | MAPT (0.79) | MAPTPOLBNR1H4TP53THRB | |
| SCHEMBL2542966 | 0.77 | MAPT (0.70) | MAPTPOLBTP53THRBMEN1 | |
| SCHEMBL2542223 | 0.77 | MAPT (0.66) | MAPTPOLBTP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2011-10-27 | — | — | US | claimed |
| US-11033545-B2 | Negative allosteric modulators of MGLUR5 for use in the treatment of mature brain damages | Sinntaxis AB (SE) | 2021-06-15 | — | — | US | disclosed |
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| WO-2010049366-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GRM5, GRM1, GRM3 | MAPT 2044/4885POLB 4360/4885NR1H4 294/4885 |
| US-11033545-B2 | Negative allosteric modulators of MGLUR5 for use in the treatment of mature brain damages | GRM5, GRIK5, GRM1 | MAPT 1070/4885POLB 3275/4885NR1H4 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.